Design Improvements of the HIA–VAD Based on Animal Experiments

Eilers, Rolf; Harbott, P.; Reul, H.; Rakhorst, Gerhard; G, Rau

doi:10.1111/j.1525-1594.1994.tb03362.x

Cited by 21 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most important design improvement after animal experiments was a new trileaflet polyurethane valve, which was designed as a blood‐pump valve with an emphasis on opening behavior and flow resistance. Hydrodynamic performance and sufficient durability of this new valve were confirmed by various in vitro tests (3). Still, the valve sinuses were the region where thrombus formation was diagnosed in most of the patients and further improvements should focus on the valve sinuses and inadequate flow patterns within the device.…”

Section: Discussionmentioning

confidence: 75%

“…With the first successful implantation of the MEDOS/HIA‐System (MEDOS), a new device for ventricular assistance in pediatric and adult patients was introduced (1). Design and pump characteristics have been previously described (2,3). The different sizes of the pump chambers (9/10 mL, 22.5/25 mL, 54/60 mL, and 72/80 mL) enable the use of the MEDOS without limitations with regard to the patients’ height and weight (4).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Mechanical Circulatory Support in Infants and Adults With the MEDOS/HIA Assist Device

Kaczmarek¹,

Mair²,

Groetzner³

et al. 2005

Artificial Organs

View full text Add to dashboard Cite

Mechanical circulatory support is successfully applied to patients with low cardiac output. The MEDOS/HIA-System provides pulsatile ventricular assistance for pediatric and adult patients. Our experience with 13 consecutive patients with the MEDOS is reported. Perioperative survival was 84.6%, complications occurred in 61% (31% thrombembolism, 23% rethoracotomy, 7% infections). Mean duration of support was 17.6 +/- 14.6 days (1-45 days). Bilirubin decreased from 3.9 +/- 2.3 to 2.7 +/- 1.6 mg/dL; creatinine from 1.6 +/- 1 to 1.4 +/- 0.8 mg/dL; lactate from 5.8 +/- 4.2 to 1.7 +/- 1.5 (P = 0.027; Wilcoxon). All patients who underwent subsequent heart transplantation (6 of 13; 46%) were discharged from hospital. For 38.5% of the patients no organ offer was received. Mechanical circulatory support with the MEDOS/HIA-System can be performed successfully for bridging to transplantation. Secondary organ functions improve under this pulsatile circulatory assistance. Hemorrhage and thromboembolic events are the most frequent complications.

show abstract

Section: Discussionmentioning

confidence: 75%

mentioning

confidence: 99%

Mechanical Circulatory Support in Infants and Adults With the MEDOS/HIA Assist Device

Kaczmarek¹,

Mair²,

Groetzner³

et al. 2005

Artificial Organs

View full text Add to dashboard Cite

show abstract

“…Polyurethane trileaflet valves are incorporated at the inlet and outlet positions. These polyurethane trileaflet valves are the same as those used within the clinically approved MEDOS HIA‐VAD with excellent hemodynamic properties (9). The pump chamber can be filled passively or actively; for active filling, the pusher plate is mechanically attached to the swash bold.…”

Section: Methodsmentioning

confidence: 99%

A Small Pulsatile Blood Pump for Ventricular Support During End‐Stage Heart Failure

Förster¹,

Kaufmann²,

Reul³

et al. 2000

Artificial Organs

View full text Add to dashboard Cite

A displacement blood pump to support the natural heart of patients for recovery from end-stage heart failure has been developed. This electromechanical pusher plate pump has a very compact and extremely flat design. The design goal was achieved by developing a novel gear system based on the principle of a swash plate. The blood pump and cannulae can be placed within the thoracic cavity between the lungs and ribcage. The first labtype model delivers an output of 3.1 L/min against an aortic pressure of 100 mm Hg at 120 bpm.

show abstract

“…The valves are manufactured by Polymedica Medizintechnik GmbH, Aachen, Germany. The complete blood chamber system is similar to the known 60 ml version of the MEDOS-HIA-VAD (Medos Medizintechnik GmbH, Stolberg, Germany) (13). Its excellent washout, minimal hemolysis, and minimum potential for thrombotic complications have been demonstrated successfully in clinical applications (14).…”

Section: Pump Unitmentioning

confidence: 99%

The Implantable Fuzzy Controlled Helmholtz‐Left Ventricular Assist Device: First In Vitro Testing

et al. 1997

View full text Add to dashboard Cite

To perform first experimental tests for validation of a new left ventricular assist device (LVAD) with a high efficiency energy converter, a new pump design and a novel type of perfusion control, a functional labtype, were manufactured. With a stroke volume of 65 ml, a total pump housing volume of 450 ml (including valves and connectors), and a weight of 430 g, it is one of the smallest and lightest implantable pulsatile electromechanical LVADs. Pulsatile operation is generated by a special reduction and displacement gear which transforms a uniform rotational movement of a sensorless. electronically commutated DC motor into a translatory pusher plate movement. A prolonged duration for filling (60% of the cycle time) supports full-empty pumping and consequently a high overall pump efficiency. Active adaptation of output flow to organ perfusion demand is achieved by changing the rotational speed of the motor by means of a sensorless fuzzy controller, which detects preload and afterload induced effects at the motor current input. First in vitro test results obtained within a circulatory mock loop that simulates physiological preloads and afterloads are presented. They comprise preload sensitivity and the function of the novel perfusion controller as well as preload and afterload related flow data. The results prove the feasability of the energy conversion with the novel gear and control concept for an implantable electromechanical pulsatile LVAD.

show abstract

Design Improvements of the HIA–VAD Based on Animal Experiments

Cited by 21 publications

References 9 publications

Mechanical Circulatory Support in Infants and Adults With the MEDOS/HIA Assist Device

Mechanical Circulatory Support in Infants and Adults With the MEDOS/HIA Assist Device

A Small Pulsatile Blood Pump for Ventricular Support During End‐Stage Heart Failure

The Implantable Fuzzy Controlled Helmholtz‐Left Ventricular Assist Device: First In Vitro Testing

Contact Info

Product

Resources

About